Apilimod mesylate is under clinical development by AI Therapeutics and currently in Phase II for Frontotemporal Dementia (FTD). According to GlobalData, Phase II drugs for Frontotemporal Dementia (FTD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Apilimod mesylate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Apilimod mesylate overview
Apilimod mesylate is under development for the treatment of follicular lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma, amyotrophic lateral sclerosis, frontotemporal dementia and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral route. It acts by targeting 1 phosphatidylinositol 3 phosphate 5 kinase (PIKFYVE). It was also under development for follicular lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary mediastinal b-cell lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
AI Therapeutics overview
AI Therapeutics is a biopharmaceutical company that identifies and develops treatments for neurological disease and cancers. It investigating LAM-001 program against pulmonary sarcoidosis and bronchiolitis obliterans disease caused after lung transplantation resulting in obstruction of the smallest airways of the lungs. The company is also evaluating AIT–101 drug to treat amyotrophic lateral sclerosis and AIT-102 for rare diseases. AI Therapeutics is headquartered in Guilford, Connecticut, the US.
For a complete picture of Apilimod mesylate’s drug-specific PTSR and LoA scores, buy the report here.